{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:32:45Z","timestamp":1777397565441,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The potential role of Alzheimer's disease (AD) pathology in contributing to cognitive impairment in \u03b1-synucleinopathies warrants in vivo detection of the pathological burden in patients with \u03b1-synucleinopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Using a fully automated platform, we measured the levels of cerebrospinal fluid (CSF) AD biomarkers, namely A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , P-tau181 and T-tau, as well as their derived ratios, P-tau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio and T-tau\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio, in a cohort of Parkinson's disease (PD), dementia with Lewy bodies (DLB), preclinical and prodromal AD (pAD) patients, as well as cognitively normal controls. We binarized the CSF biomarkers and determined the proportion of individuals with abnormal biomarker levels within each diagnostic group. We explored the associations between these biomarkers and cognitive performance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study consisted of 51 controls, 46 PD, 65 DLB, and 50 pAD patients. CSF biomarkers were measured using Roche Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      immunoassays. Cognitive performance was based on Mini-Mental State Examination (MMSE).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CSF P-tau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      and T-tau\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratios were increased in DLB and pAD, but not PD, compared with controls. Both DLB and pAD had higher proportions of individuals with abnormal CSF P-tau181\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio (AD\u2009=\u2009100%, DLB\u2009=\u200959%, PD\u2009=\u200937% and controls\u2009=\u200926%) and T-tau\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio (AD\u2009=\u2009100%, DLB\u2009=\u200951%, PD\u2009=\u200926% and controls\u2009=\u200918%). Within each diagnostic group, there was no association between CSF AD biomarkers and cognition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      CSF AD biomarkers profile is prevalent in DLB. Our findings highlight the potential utility of Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      immunoassay platform for the evaluation of AD pathology in \u03b1-synucleinopathies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251360404","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:49:22Z","timestamp":1753685362000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays"],"prefix":"10.1177","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2869-0096","authenticated-orcid":false,"given":"Joyce Ruifen","family":"Chong","sequence":"first","affiliation":[{"name":"Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK"},{"name":"Department of Pharmacology, National University of Singapore, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Hye","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-3009","authenticated-orcid":false,"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[{"name":"Ace Alzheimer Center Barcelona \u2013 Universitat Internacional de Catalunya, Barcelona, Spain"},{"name":"Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-3802","authenticated-orcid":false,"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK"},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0348-0"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(13)70017-8"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"e_1_3_4_5_2","first-page":"216","article-title":"Regional overlap of pathologies in Lewy body disorders","volume":"76","author":"Colom-Cadena M","year":"2017","unstructured":"Colom-Cadena M, Grau-Rivera O, Planellas L, et al. Regional overlap of pathologies in Lewy body disorders. J Neuropathol Exp Neurol 2017; 76: 216\u2013224.","journal-title":"J Neuropathol Exp Neurol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12182"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0000000000000018"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165987.89198.65"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00066-1"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.805135"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00462-6"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050612"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13390"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160322"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26668"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.010"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.09.009"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00595-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.013"},{"key":"e_1_3_4_22_2","article-title":"P-tau\/A\u03b242 and A\u03b242\/40 ratios in CSF are equally predictive of amyloid PET status","volume":"13","author":"Campbell MR","year":"2021","unstructured":"Campbell MR, Ashrafzadeh-Kian S, Petersen RC, et al. P-tau\/A\u03b242 and A\u03b242\/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst) 2021; 13: e12190.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.2814"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.105"},{"key":"e_1_3_4_25_2","unstructured":"Roche Alzheimer\u2019s disease Cerebrospinal Fluid (CSF) assays receive FDA clearance supporting more accurate and timely diagnosis https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2022\/roche-alzheimers-disease-cerebrospinal-fluid-assays-receive-fda-clearance.html (accessed Jun 12 2024)."},{"key":"e_1_3_4_26_2","unstructured":"Roche receives FDA clearance for additional Alzheimer\u2019s disease Cerebrospinal Fluid (CSF) assays supporting timely diagnosis and treatment decision-making https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2023\/roche-fda-clearance-additional-alzheimers-disease-cerebrospinal-fluid-ttau.html (accessed Jun 12 2024)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.27"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28545"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00374-w"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320980"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.03.006"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170274"},{"key":"e_1_3_4_33_2","article-title":"Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia","volume":"13","author":"Giil LM","year":"2021","unstructured":"Giil LM, Aarsland D, Vik-Mo AO. Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. Alzheimers Dement (Amst) 2021; 13: e12152.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000165917"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99794-9"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170231"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187889.17253.b1"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000916"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000514052"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-017-0062-5"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww015"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.03.001"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2022.10.015"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24825"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12897"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-016-1517-6"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01003-w"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251360404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251360404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251360404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:11:17Z","timestamp":1777371077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251360404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":49,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/13872877251360404"],"URL":"https:\/\/doi.org\/10.1177\/13872877251360404","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]}}}